Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Prostatic Neoplasms

Neoplasm Metastasis

Prostatic Diseases

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Male Urogenital Diseases

Susan Slovin, MD

The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.

The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.

Human tissue, body fluids, and blood Fresh tissue will be obtained from patients undergoing a biopsy or surgical procedure as part of their standard therapy or as part of an investigational research protocol. Previously stored pathology specimens may also be used. Peripheral blood, bone marrow, urine, and other bodily fluids and samples will also be obtained as needed.

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Rockefeller University

Flinders Medical Centre

University of Southern California

Gen-Probe, Incorporated

Genentech, Inc.

General Electric

Purdue University

Biocept, Inc.

Duke University

Ikonysis

Array Genomics

Cold Spring Harbor Laboratory

Nodality

Epic Sciences

Rutgers Cancer Institute of New Jersey

Dana-Farber Cancer Institute

Johns Hopkins University

M.D. Anderson Cancer Center

Oregon Health and Science University

University of California, San Francisco

University of Chicago

University of Michigan

University of Washington

University of Wisconsin, Madison

Fred Hutchinson Cancer Center

Broad Institute

Weill Medical College of Cornell University

Institute of Cancer Research, United Kingdom

Vitatex Inc.

Serametrix Corporation

Promega Corporation

Creatv Microtech, Inc.

Viatar LLC

Massachusetts Institute of Technology

Advanced Cell Diagnostics

ApoCell, Inc.

Beckman Coulter GmbH

Bioview, Inc.

Clearbridge BioMedics Pte Ltd., Singapore

Cynvenio Biosystems

Exosome Diagnostics, Inc.

Fluxion Biosciences

Foundation Medicine

Universitätsklinikum Hamburg-Eppendorf

Brooklyn ImmunoTherapeutics, LLC

Ohio State University

Palo Alto Research Center

Rarecells

Silicon Biosystems

The Scripps Research Institute

University of Minnesota

Janssen Diagnostics, LLC

University of Regensburg

Innocrin Pharmaceuticals Inc.

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Eligibility	Organization
Molecular Studies and Clinical Correlations in Human Prostatic Disease	NCT00578240	Prostate Cancer	-	Memorial Sloan Kettering Cancer Center
Molecular Studies and Clinical Correlations in Human Prostatic Disease	NCT00578240	Prostate Cancer	-	Memorial Sloan Kettering Cancer Center
Molecular Studies and Clinical Correlations in Human Prostatic Disease	NCT00578240	Prostate Cancer	-	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for clinical metastases